Johnson & Johnson is listed among the 12 Most Profitable Dividend Stocks to Buy in 2026. Guggenheim analyst raised the price target on JNJ to $240 after solid Q4 results. Despite headwinds like drug pricing agreement with Trump administration, JNJ forecasts 2026 sales between $99.5B and $100.5B, with profit slightly ahead of estimates.

The company operates in healthcare with drug development, medical devices, and global product sales. Although JNJ is seen as a good investment, some believe certain AI stocks offer greater potential. A free report on the best short-term AI stock is available for those looking for upside potential and benefit from Trump-era tariffs.

Overall, Johnson & Johnson continues to demonstrate strength in the healthcare sector with positive outlook for 2026 despite challenges like drug pricing agreements and tariff-related costs.

Read more at Yahoo Finance: Guggenheim Lifts Johnson & Johnson (JNJ) Outlook After Solid Q4 and 2026 Guide